Send me real-time posts from this site at my email

Trading List: March 3 - TGTX - TG Therapeutics - Business Update

$TGTX - On our trading list. Just reported earnings Tuesday morning and gave us details about the goals this year and their cash balances. Looks like a ton of potential here still. This is one of our highest picks.

TG Therapeutics announces key objectives for 2020

Report topline PFS results from the Phase 3 UNITY-CLL trial evaluating U2 in patients with frontline and previously treated CLL, and if successful, target a potential New Drug Application/Biologics Licensing Application submission by year-end. Complete rolling NDA submission for umbralisib in patients with previously treated MZL and FL, in the first half of 2020. Report topline results from the Phase 3 ULTIMATE I & II trials in RMS, in the second half of 2020. Continue to advance our early pipeline candidates including TG-1501, TG-1701 and TG-1801.

TG Therapeutics expects cash to fund operations 'well into' 2021

Cash, cash equivalents and investment securities were $140.4 million as of December 31, 2019. The Company believes its cash, cash equivalents and investment securities on hand as of December 31, 2019, will be sufficient to fund the Company's planned operations well into 2021.

$TGTX, TG Therapeutics, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue